Karyopharm Therapeutics

KPTI

Market cap $163M

KPTI Hedge Fund Activity: Q1 2026 in Review

77 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2026, worth a combined $102M — up 47% from $69.6M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new KPTI positions and 15 closed out — a net gain of 10 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was Commodore Capital, opening a new position worth an estimated $14.9M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.84M sold.

• 77 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2026, up from 69 in Q4 2025.
• Funds reported $102M of Karyopharm Therapeutics stock for Q1 2026, up 47% quarter-over-quarter.
• 25 funds opened new Karyopharm Therapeutics positions in Q1 2026 and 15 closed out, a net change of +10 holders.
• The largest Karyopharm Therapeutics buyer in Q1 2026 was Commodore Capital, an estimated $14.9M added.
• The largest Karyopharm Therapeutics seller in Q1 2026 was Opaleye Management, an estimated $6.84M sold.

Based on aggregated 13F filings for Q1 2026.